SAPA-China 2025 Keynote by Zheng Lingxiao, CEO of Ruixing Medical: AI-Powered Surgical Robots and the Future Smart Operating Room
RaysightMed
Medical Imaging Product Developer
Recently, the SAPA-China 2025 Pharmaceutical Industry Conference was held at the Suzhou Lion Mountain International Convention Center. Zheng Lingxiao, founder and CEO of RaysightMed, was invited to attend and delivered a speech titled "AI Empowers Surgical Robots, Building the Future Intelligent Operating Room" delivered a keynote speech, sharing the technological innovations and application achievements of the full-process intelligent solution for cardiovascular and cerebrovascular diseases.
RaysightMed Founder and CEO Lingxiao Zheng Attended the Meeting (Left)
The theme of this conference is "Building an Innovative Ecosystem, Opening a New Era of Medicine," hosted by the Chinese Chapter of the Sino-American Pharmaceutical Association and guided by the Suzhou New District Management Committee.Attracting more than ten thousand experts and scholars from top global research institutions, as well as leading figures from large multinational pharmaceutical and biotechnology innovation enterprises.`, to jointly discuss key issues in the biopharmaceutical field such as cutting-edge technologies, product development, clinical implementation, achievement transformation, and international collaboration.`
RaysightMed founder and CEO Zheng Lingxiao introduced: "What we have builtThe AI + Surgical Robot Precision Diagnosis and Treatment Platform for Cardiovascular and Cerebrovascular Diseases Achieves a Full-process Intelligent Closed-loop from Preoperative Imaging Diagnosis and Surgical Planning, Intraoperative Navigation and Fully Automatic Execution of Vascular Intervention Surgeries, to Postoperative Systematic Health Management.。”
He further explained that before the surgery, RuiXin-FFR by RaysightMed evaluates coronary blood supply function based on non-invasive CT imaging, calculates Fractional Flow Reserve (FFR) values, provides plaque stability assessment and surgical planning, and screens for lesions in advance. During the surgery, AngioQFA, combined with a fully automatic AI vascular interventional surgical robot, creates an intelligent operating room solution. Specifically, it is based on coronary angiography images.AngioQFA can simultaneously obtain the patient's coronary fractional flow reserve (FFR) and index of microcirculatory resistance (IMR) in a single analysis, enabling non-invasive and comprehensive assessment of the impact of coronary stenosis on myocardial blood supply and microcirculatory function.ResonanceAt the same time, the fully automatic AI vascular interventional surgical robot can make decisions and perform operations automatically and intelligently, significantly improving the efficiency and success rate of the surgery. In the postoperative stage, RaysightMed's systematic health management plan effectively predicts the risk of in-stent restenosis through dual morphological and functional assessments, and achieves scientific patient follow-up and cardiac rehabilitation management.，Effectively improve patients' long-term prognosis and quality of life.
Currently, RaysightMedMore than 800 clinical cooperation hospitals, with over 200,000 patients safely using the product, with a diagnostic accuracy rate reaching the international gold standard level. At the same time, the company has supported over 40 cardiovascular centers and enrolled more than 4,600 cases in a large-scale, multi-center prospective non-invasive functional clinical study.
Continuous Innovation, Empowering High-Quality Industrial Development
The impressive appearance at the high-profile international platform of SAPA-China 2025 fully demonstrates RaysightMed's technological innovation and international influence in the field of precision diagnosis and treatment of cardiovascular and cerebrovascular diseases.
Looking ahead, RaysightMed will continue to deepen the integration and innovative application of AI and robotics in the cardiovascular and cerebrovascular fields, constantly optimizing and improving the full-process intelligent diagnosis and treatment platform for cardiovascular and cerebrovascular diseases. The company will promote the high-quality development of the biopharmaceutical industry in China and even globally with continuous technological breakthroughs and clinically effective value.
